Free Trial
→ Market Panic: Trump Just Dropped a Bomb on Your Stocks (From American Alternative) (Ad) Buy ARQT Stock  Free ARQT Stock Alerts

Arcutis Biotherapeutics (ARQT) Financials

Arcutis Biotherapeutics logo
$13.58 -0.56 (-3.96%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$13.75 +0.17 (+1.25%)
As of 07:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Arcutis Biotherapeutics

Annual Income Statements for Arcutis Biotherapeutics

This table shows Arcutis Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Income / (Loss) Attributable to Common Shareholders		 -140 -262 -311 -206 -136 -42 -19
Consolidated Net Income / (Loss)		 -140 -262 -311 -206 -136 -42 -19
Net Income / (Loss) Continuing Operations		 -140 -262 -311 -206 -136 -42 -19
Total Pre-Tax Income 		-156 -259 -311 -206 -136 -42 -19
Total Operating Income		 -128 -241 -302 -207 -137 -43 -20
Total Gross Profit		 177 55 2.93 0.00 0.00 0.00 0.00
Total Revenue		 197 60 3.69 0.00 0.00 0.00 0.00
Operating Revenue		 197 60 3.69 0.00 0.00 - -
Total Cost of Revenue		 19 4.99 0.75 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 19 4.99 0.75 0.00 0.00 - -
Total Operating Expenses		 306 296 305 207 137 43 20
Selling, General & Admin Expense		 229 185 122 61 21 6.61 1.80
Research & Development Expense		 76 111 182 146 115 37 18
Total Other Income / (Expense), net		 -27 -18 -9.83 0.17 0.97 1.14 0.48
Interest Expense		 27 30 16 0.00 0.00 - -
Income Tax Expense		 0.65 3.11 0.00 - - - -
Other Gains / (Losses), net		 16 - - - - - -
Basic Earnings per Share		 ($1.16) ($3.78) ($5.66) ($4.18) ($3.80) ($22.78) ($15.53)
Weighted Average Basic Shares Outstanding		 120.96M 69.31M 55.03M 49.41M 35.67M 1.84M 1.24M
Diluted Earnings per Share		 ($1.16) ($3.78) ($5.66) ($4.18) ($3.80) ($22.78) ($15.53)
Weighted Average Diluted Shares Outstanding		 120.96M 69.31M 55.03M 49.41M 35.67M 1.84M 1.24M
Weighted Average Basic & Diluted Shares Outstanding		 118.64M - 61.08M 50.38M 35.67M 1.84M 1.24M

Quarterly Income Statements for Arcutis Biotherapeutics

This table shows Arcutis Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -25 -11 -42 -52 -35 -66 -45 -71 -80 -72 -108
Consolidated Net Income / (Loss)		 -25 -11 -42 -52 -35 -66 -45 -71 -80 -72 -108
Net Income / (Loss) Continuing Operations		 -25 -11 -42 -52 -35 -66 -45 -71 -80 -72 -108
Total Pre-Tax Income 		-25 -27 -42 -52 -35 -66 -42 -71 -80 -72 -108
Total Operating Income		 -25 -7.63 -39 -50 -32 -61 -37 -67 -76 -68 -105
Total Gross Profit		 57 64 39 27 46 11 37 4.41 2.00 2.48 0.46
Total Revenue		 66 71 45 31 50 14 38 5.19 2.78 2.96 0.73
Operating Revenue		 66 71 45 31 50 14 38 5.19 2.78 - 0.73
Total Cost of Revenue		 8.83 6.91 5.50 3.46 3.26 2.25 1.18 0.78 0.78 0.49 0.27
Operating Cost of Revenue		 8.83 6.91 5.50 3.46 3.26 2.25 1.18 0.78 0.78 - 0.27
Total Operating Expenses		 82 72 78 77 78 72 74 71 78 71 105
Selling, General & Admin Expense		 64 58 59 58 55 49 48 46 43 37 35
Research & Development Expense		 18 14 20 19 23 24 26 25 35 34 70
Total Other Income / (Expense), net		 -0.25 -19 -2.47 -2.26 -3.44 -5.03 -4.84 -4.23 -3.84 -3.60 -2.96
Interest Expense		 2.98 5.55 6.65 7.48 7.48 7.76 7.56 7.35 7.04 6.92 4.90
Other Income / (Expense), net		 2.73 - 4.18 5.23 4.04 2.74 2.72 3.12 3.21 3.32 1.94
Income Tax Expense		 0.28 0.32 0.00 0.00 0.32 0.09 3.02 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.20) ($0.09) ($0.33) ($0.42) ($0.32) ($0.58) ($0.73) ($1.16) ($1.31) ($1.19) ($1.89)
Weighted Average Basic Shares Outstanding		 126.04M 120.96M 124.30M 123.48M 111.05M 69.31M 61.73M 61.43M 61.17M 55.03M 57.09M
Diluted Earnings per Share		 ($0.20) ($0.09) ($0.33) ($0.42) ($0.32) ($0.58) ($0.73) ($1.16) ($1.31) ($1.19) ($1.89)
Weighted Average Diluted Shares Outstanding		 126.04M 120.96M 124.30M 123.48M 111.05M 69.31M 61.73M 61.43M 61.17M 55.03M 57.09M
Weighted Average Basic & Diluted Shares Outstanding		 119.20M 118.64M 117.04M 116.89M 115.76M 0.00 94.38M 61.65M 61.42M 61.08M 60.93M

Annual Cash Flow Statements for Arcutis Biotherapeutics

This table details how cash moves in and out of Arcutis Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Change in Cash & Equivalents		 -17 34 -43 31 3.29 24 36
Net Cash From Operating Activities		 -112 -247 -258 -175 -113 -43 -14
Net Cash From Continuing Operating Activities		 -112 -247 -258 -175 -113 -43 -14
Net Income / (Loss) Continuing Operations		 -140 -262 -311 -206 -136 -42 -19
Consolidated Net Income / (Loss)		 -140 -262 -311 -206 -136 -42 -19
Depreciation Expense		 0.64 0.77 0.62 0.45 0.12 0.07 0.00
Amortization Expense		 -4.94 -6.24 -1.94 3.45 0.07 -0.35 -0.01
Non-Cash Adjustments To Reconcile Net Income		 47 44 65 24 8.32 0.95 3.08
Changes in Operating Assets and Liabilities, net		 -15 -24 -10 3.62 14 -1.51 2.11
Net Cash From Investing Activities		 29 180 -87 -76 -182 -26 -12
Net Cash From Continuing Investing Activities		 29 180 -87 -76 -182 -26 -12
Purchase of Property, Plant & Equipment		 -0.14 -0.43 -0.33 -1.00 -0.32 -0.30 0.00
Acquisitions		 -5.00 0.00 -23 0.00 0.00 - -
Purchase of Investments		 -255 -226 -415 -293 -279 -61 -12
Sale and/or Maturity of Investments		 289 407 351 218 98 35 0.00
Net Cash From Financing Activities		 66 101 302 282 298 93 62
Net Cash From Continuing Financing Activities		 66 101 302 282 298 93 62
Repayment of Debt		 -100 0.00 -2.19 -1.64 0.00 -1.40 0.00
Issuance of Debt		 0.00 0.00 125 74 0.00 0.00 -
Issuance of Common Equity		 163 100 178 208 298 0.00 0.00
Other Financing Activities, net		 2.81 1.25 1.02 1.27 0.53 0.27 0.39
Effect of Exchange Rate Changes		 -0.24 -0.05 0.00 - - - -
Cash Interest Paid		 22 25 13 0.14 0.00 0.00 -

Quarterly Cash Flow Statements for Arcutis Biotherapeutics

This table details how cash moves in and out of Arcutis Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -18 -64 51 -106 101 -19 2.36 24 27 -28 20
Net Cash From Operating Activities		 -30 -0.75 -35 -45 -32 -56 -44 -66 -80 -71 -68
Net Cash From Continuing Operating Activities		 -30 -0.75 -35 -44 -32 -56 -44 -66 -80 -71 -68
Net Income / (Loss) Continuing Operations		 -25 -11 -42 -52 -35 -66 -45 -71 -80 -72 -108
Consolidated Net Income / (Loss)		 -25 -11 -42 -52 -35 -66 -45 -71 -80 -72 -108
Depreciation Expense		 0.15 0.15 0.16 0.16 0.17 0.20 0.20 0.20 0.18 0.16 0.16
Amortization Expense		 2.12 -0.78 -0.42 -2.20 -1.54 -1.29 -1.35 -1.64 -1.97 -2.16 -0.68
Non-Cash Adjustments To Reconcile Net Income		 10 12 10 14 11 11 11 12 11 10 39
Changes in Operating Assets and Liabilities, net		 -18 -1.57 -3.80 -4.27 -5.44 0.41 -9.18 -5.73 -9.01 -7.41 1.23
Net Cash From Investing Activities		 12 35 85 -62 -29 -62 46 89 108 42 -197
Net Cash From Continuing Investing Activities		 12 35 85 -62 -29 -62 46 89 108 42 -197
Purchase of Property, Plant & Equipment		 -0.61 - -0.14 - 0.00 -0.01 -0.06 -0.28 -0.08 -0.12 -0.01
Purchase of Investments		 -56 -17 -5.69 -126 -106 -118 -22 -46 -40 -38 -242
Sale and/or Maturity of Investments		 68 57 91 64 77 56 68 135 148 80 67
Net Cash From Financing Activities		 0.40 -97 0.39 1.46 162 99 0.87 1.07 0.10 0.96 285
Net Cash From Continuing Financing Activities		 0.40 -97 0.39 1.46 162 99 0.87 1.07 0.10 0.96 285
Issuance of Common Equity		 0.00 1.06 - 0.65 162 99 - 0.99 0.00 0.95 162
Other Financing Activities, net		 0.40 1.53 0.39 0.81 0.08 0.21 0.87 0.07 0.10 0.02 0.58
Effect of Exchange Rate Changes		 0.00 -0.23 0.10 -0.03 -0.07 0.07 -0.08 0.01 -0.05 - -
Cash Interest Paid		 2.57 2.96 6.23 6.51 6.51 6.58 6.55 6.31 6.00 5.71 3.93

Annual Balance Sheets for Arcutis Biotherapeutics

This table presents Arcutis Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 349 341 449 408 298 107
Total Current Assets		 336 330 437 403 293 106
Cash & Equivalents		 71 88 54 96 65 63
Restricted Cash		 0.62 0.93 1.23 1.54 1.54 0.00
Short-Term Investments		 157 183 356 291 219 38
Accounts Receivable		 73 26 8.46 0.00 - -
Inventories, net		 15 13 7.51 0.00 - -
Prepaid Expenses		 20 19 11 14 6.84 5.21
Plant, Property, & Equipment, net		 1.04 1.54 1.88 2.26 2.02 0.23
Total Noncurrent Assets		 12 9.40 9.99 3.12 3.43 0.31
Intangible Assets		 9.48 6.44 7.19 0.00 - -
Other Noncurrent Operating Assets		 2.55 2.96 2.80 3.12 3.43 0.31
Total Liabilities & Shareholders' Equity		 349 341 449 408 298 107
Total Liabilities		 191 253 240 110 28 5.55
Total Current Liabilities		 81 47 38 33 23 5.24
Accounts Payable		 14 12 8.83 7.35 7.14 1.41
Accrued Expenses		 66 34 28 26 15 3.65
Other Current Liabilities		 0.82 0.74 0.66 0.43 0.00 0.18
Total Noncurrent Liabilities		 110 206 202 77 5.05 0.31
Long-Term Debt		 107 202 198 72 - -
Other Noncurrent Operating Liabilities		 3.13 4.23 4.12 4.80 5.05 0.31
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 158 89 210 298 271 -65
Total Preferred & Common Equity		 158 89 210 298 271 -65
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 158 89 210 298 271 -65
Common Stock		 1,279 1,071 930 706 473 1.24
Retained Earnings		 -1,122 -982 -720 -408 -202 -66
Accumulated Other Comprehensive Income / (Loss)		 -0.01 0.00 -1.09 -0.26 -0.00 -0.00

Quarterly Balance Sheets for Arcutis Biotherapeutics

This table presents Arcutis Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 344 437 445 479 293 321 379 509
Total Current Assets		 324 424 435 468 282 309 368 497
Cash & Equivalents		 53 135 84 190 107 105 81 82
Restricted Cash		 0.62 0.62 0.62 0.62 0.93 0.93 0.93 1.23
Short-Term Investments		 145 196 278 214 120 164 251 395
Accounts Receivable		 85 60 43 37 19 17 13 2.43
Inventories, net		 17 14 14 13 14 10 8.55 4.31
Prepaid Expenses		 23 18 14 13 20 12 13 12
Plant, Property, & Equipment, net		 1.50 1.19 1.35 1.37 1.74 1.87 2.07 1.94
Total Noncurrent Assets		 19 12 8.82 9.11 9.68 9.95 9.71 10
Intangible Assets		 17 9.79 6.06 6.25 6.63 6.81 7.00 7.38
Other Noncurrent Operating Assets		 2.44 2.66 2.76 2.86 3.05 3.14 2.71 2.88
Total Liabilities & Shareholders' Equity		 344 437 445 479 293 321 379 509
Total Liabilities		 201 281 258 254 246 240 240 238
Total Current Liabilities		 91 172 51 47 42 37 37 37
Accounts Payable		 25 19 7.94 13 13 17 12 8.67
Accrued Expenses		 66 53 43 34 28 19 24 28
Other Current Liabilities		 0.84 0.80 0.78 0.76 0.72 0.70 0.68 0.64
Total Noncurrent Liabilities		 110 108 207 206 204 204 203 201
Long-Term Debt		 108 105 204 203 201 200 199 197
Other Noncurrent Operating Liabilities		 2.70 3.19 3.17 3.49 3.57 3.76 3.94 4.29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 143 157 186 225 47 81 140 271
Total Preferred & Common Equity		 143 157 186 225 47 81 140 271
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 143 157 186 225 47 81 140 271
Common Stock		 1,290 1,267 1,256 1,242 963 952 940 920
Retained Earnings		 -1,147 -1,111 -1,070 -1,017 -916 -871 -800 -648
Accumulated Other Comprehensive Income / (Loss)		 -0.14 0.53 -0.29 -0.13 -0.18 -0.29 -0.41 -1.60

Annual Metrics And Ratios for Arcutis Biotherapeutics

This table displays calculated financial ratios and metrics derived from Arcutis Biotherapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Growth Metrics		 - - - - - - -
Revenue Growth		 229.74% 1,517.09% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 43.48% 20.98% -46.77% -49.43% -220.43% -119.43% 0.00%
EBIT Growth		 44.01% 22.48% -43.35% -52.09% -223.07% -118.10% 0.00%
NOPAT Growth		 46.75% 20.07% -46.05% -51.14% -216.81% -118.56% 0.00%
Net Income Growth		 46.58% 15.83% -50.93% -52.09% -223.07% -118.10% 0.00%
EPS Growth		 69.31% 33.22% -35.41% -10.00% 83.32% -46.68% 0.00%
Operating Cash Flow Growth		 54.60% 4.14% -47.58% -54.49% -163.87% -204.13% 0.00%
Free Cash Flow Firm Growth		 42.94% 16.05% -60.05% -76.49% -163.55% 0.00% 0.00%
Invested Capital Growth		 104.59% 609.07% 81.30% -20.91% -7,897.97% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 21.54% 408.41% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 3.13% 1.07% -22.12% -18.44% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 2.83% 2.06% -22.05% -18.81% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 2.92% 0.94% -21.98% -18.23% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 2.14% -0.22% -22.05% -18.81% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 13.90% 4.23% -21.51% 60.21% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 5.66% -8.12% -12.31% -16.22% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -921.49% 6.89% -8.62% -9.29% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 20.29% -9.16% 67.45% -219.31% 7.69% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 90.27% 91.63% 79.54% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -67.52% -393.89% -8,060.91% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -65.33% -404.49% -8,183.04% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -65.33% -384.72% -8,025.12% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -71.25% -439.79% -8,449.76% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 90.02% 101.20% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 121.16% 112.96% 105.29% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -333.80% -2,375.88% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -281.64% -2,310.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 220.04% 2,200.09% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -113.76% -175.79% -122.80% -72.62% -72.93% -41.39% 0.00%
Cash Return on Invested Capital (CROIC)		 -402.47% -1,074.23% 0.00% 0.00% 0.00% -30,852.18% 0.00%
Operating Return on Assets (OROA)		 -37.20% -58.01% -69.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -40.58% -66.31% -72.65% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -113.76% -175.79% -122.80% -72.62% -40.30% 26.53% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -88.89% -295.65% -148.61% -69.32% -50.14% 64.58% 0.00%
Net Operating Profit after Tax (NOPAT)		 -90 -169 -211 -145 -96 -30 -14
NOPAT Margin		 -45.73% -283.14% -5,728.13% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -52.15% -65.74% -37.91% -20.52% -20.67% -23.31% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -33.95% -58.10% -51.83% - - - -
Cost of Revenue to Revenue		 9.73% 8.37% 20.46% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 116.71% 310.61% 3,313.19% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 38.88% 185.51% 4,949.40% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 155.60% 496.12% 8,262.59% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -128 -229 -296 -206 -136 -42 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -133 -235 -297 -202 -135 -42 -19
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 10.35 3.44 4.30 3.50 4.54 0.00 0.00
Price to Tangible Book Value (P/TBV)		 11.01 3.71 4.46 3.50 4.54 0.00 0.00
Price to Revenue (P/Rev)		 8.30 5.11 244.64 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 41.72 13.23 0.00 0.00 0.00 1,140.11 0.00
Enterprise Value to Revenue (EV/Rev)		 7.68 3.92 186.84 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.68 2.28 0.94 0.24 0.00 0.00 0.00
Long-Term Debt to Equity		 0.68 2.28 0.94 0.24 0.00 0.00 0.00
Financial Leverage		 -0.78 -0.95 -1.04 -1.06 -1.04 -1.00 0.00
Leverage Ratio		 2.80 2.65 1.69 1.24 1.09 1.05 0.00
Compound Leverage Factor		 3.40 2.99 1.78 1.24 1.09 1.05 0.00
Debt to Total Capital		 40.49% 69.47% 48.55% 19.55% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 40.49% 69.47% 48.55% 19.55% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 164.09% 0.00%
Common Equity to Total Capital		 59.51% 30.53% 51.45% 80.45% 100.00% -64.09% 0.00%
Debt to EBITDA		 -0.81 -0.86 -0.67 -0.36 0.00 0.00 0.00
Net Debt to EBITDA		 0.91 0.30 0.72 1.56 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.81 -0.86 -0.67 -0.36 0.00 0.00 0.00
Debt to NOPAT		 -1.19 -1.20 -0.94 -0.50 0.00 0.00 0.00
Net Debt to NOPAT		 1.35 0.42 1.01 2.19 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.19 -1.20 -0.94 -0.50 0.00 0.00 0.00
Altman Z-Score		 0.84 -4.35 -1.08 3.68 25.28 16.20 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 44.75% 164.09% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 4.15 7.08 11.57 12.09 12.96 20.33 0.00
Quick Ratio		 3.72 6.38 11.06 11.61 12.58 19.34 0.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 -108 -190 -226 -141 -80 -30 0.00
Operating Cash Flow to CapEx		 -78,432.17% -57,723.60% -77,391.89% -17,550.45% -35,212.77% -14,520.68% 0.00%
Free Cash Flow to Firm to Interest Expense		 -3.99 -6.39 -14.45 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -4.13 -8.32 -16.47 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.13 -8.33 -16.49 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.57 0.15 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 3.98 3.48 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 1.38 0.48 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 152.36 34.86 1.78 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 1.46 0.48 0.09 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 91.81 104.91 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 263.90 755.62 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 250.09 761.87 3,916.25 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 105.62 98.65 -3,916.25 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 36 18 -3.47 -19 -15 0.20 0.00
Invested Capital Turnover		 7.30 8.39 -0.33 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 18 21 15 -3.21 -16 0.20 0.00
Enterprise Value (EV)		 1,509 234 689 727 941 225 0.00
Market Capitalization		 1,630 305 902 1,043 1,227 159 159
Book Value per Share		 $1.35 $0.94 $3.44 $5.92 $6.20 ($35.28) $0.00
Tangible Book Value per Share		 $1.27 $0.87 $3.32 $5.92 $6.20 ($35.28) $0.00
Total Capital		 265 290 407 370 271 101 0.00
Total Debt		 107 202 198 72 0.00 0.00 0.00
Total Long-Term Debt		 107 202 198 72 0.00 0.00 0.00
Net Debt		 -121 -71 -213 -316 -286 -101 0.00
Capital Expenditures (CapEx)		 0.14 0.43 0.33 1.00 0.32 0.30 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 26 11 -11 -19 -16 -0.03 0.00
Debt-free Net Working Capital (DFNWC)		 255 284 400 369 270 101 0.00
Net Working Capital (NWC)		 255 284 400 369 270 101 0.00
Net Nonoperating Expense (NNE)		 50 93 100 62 40 12 5.44
Net Nonoperating Obligations (NNO)		 -121 -71 -213 -316 -286 -101 0.00
Total Depreciation and Amortization (D&A)		 -4.30 -5.47 -1.32 3.91 0.19 -0.29 -0.01
Debt-free, Cash-free Net Working Capital to Revenue		 13.35% 18.42% -304.50% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 129.65% 476.06% 10,840.99% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 129.65% 476.06% 10,840.99% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($1.16) $0.00 ($5.66) ($4.18) ($3.80) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 120.96M 0.00 55.03M 49.41M 50.08M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($1.16) $0.00 ($5.66) ($4.18) ($3.80) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 120.96M 0.00 55.03M 49.41M 50.08M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($3.80) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 118.64M 0.00 61.08M 50.38M 35.67M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -90 -169 -211 -145 -96 -30 -14
Normalized NOPAT Margin		 -45.73% -283.14% -5,728.13% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -79.15% -434.57% -8,449.76% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -4.73 -7.72 -18.90 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -3.31 -5.68 -13.49 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -4.73 -7.73 -18.92 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3.31 -5.69 -13.51 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Arcutis Biotherapeutics

This table displays calculated financial ratios and metrics derived from Arcutis Biotherapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 32.84% 427.58% 17.44% 494.57% 1,682.42% 356.81% 5,156.41% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 32.54% 86.11% 0.52% 27.96% 61.33% 11.30% 65.81% -0.16% -21.29% 4.56% -85.48%
EBIT Growth		 20.96% 86.94% -2.05% 29.53% 62.25% 10.25% 66.75% 2.70% -16.92% 8.72% -80.43%
NOPAT Growth		 22.43% 87.52% -5.86% 24.99% 58.54% 10.60% 64.77% -1.42% -21.77% 4.01% -83.52%
Net Income Growth		 29.17% 83.72% 7.21% 26.28% 55.83% 7.96% 58.44% -5.32% -24.53% -0.97% -89.03%
EPS Growth		 37.50% 84.48% 54.79% 63.79% 75.57% 51.26% 61.38% 11.45% -3.15% 17.36% -65.79%
Operating Cash Flow Growth		 3.87% 98.67% 21.14% 32.14% 60.67% 20.86% 35.03% -7.27% -41.02% -37.43% -65.58%
Free Cash Flow Firm Growth		 -13.04% 62.74% 32.18% 28.69% 47.66% -1.55% 18.26% -161.80% -266.17% -34.93% -34.84%
Invested Capital Growth		 121.70% 104.59% 54.51% 154.53% 350.38% 609.07% 282.40% 171.76% 128.19% 81.30% -83.43%
Revenue Q/Q Growth		 -7.73% 59.45% 45.04% -37.75% 0.00% -64.51% 634.28% 86.62% -6.08% 308.41% 0.00%
EBITDA Q/Q Growth		 -136.11% 76.47% 25.04% -61.98% 0.00% -68.48% 45.72% 13.06% -11.56% 35.06% -59.02%
EBIT Q/Q Growth		 -185.63% 78.12% 22.22% -62.62% 0.00% -70.94% 46.29% 12.89% -12.22% 36.68% -57.19%
NOPAT Q/Q Growth		 -221.40% 80.46% 21.99% -58.36% 0.00% -65.75% 44.72% 12.46% -11.46% 34.68% -59.13%
Net Income Q/Q Growth		 -132.30% 74.03% 20.63% -47.91% 0.00% -48.07% 36.94% 11.37% -11.22% 33.14% -59.79%
EPS Q/Q Growth		 -122.22% 72.73% 21.43% -31.25% 0.00% 20.55% 37.07% 11.45% -10.08% 37.04% -44.27%
Operating Cash Flow Q/Q Growth		 -3,961.50% 97.84% 23.12% -42.77% 0.00% -27.87% 33.84% 17.25% -13.06% -4.98% -9.22%
Free Cash Flow Firm Q/Q Growth		 -90.81% 37.20% 26.38% -28.15% 0.00% -14.31% 22.59% 5.95% -22.02% 7.99% -147.95%
Invested Capital Q/Q Growth		 42.57% 20.29% 10.63% 16.85% 0.00% -9.16% 82.25% 106.76% 248.72% 67.45% 28.30%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 86.59% 90.32% 87.70% 88.77% 93.43% 83.39% 96.90% 85.05% 71.84% 83.62% 62.90%
EBITDA Margin		 -29.65% -11.59% -78.53% -151.94% -58.39% -440.03% -92.70% -1,253.95% -2,691.69% -2,266.09% -14,252.28%
Operating Margin		 -37.25% -10.70% -87.29% -162.28% -63.79% -452.23% -96.84% -1,286.38% -2,742.36% -2,310.84% -14,448.00%
EBIT Margin		 -33.11% -10.70% -77.94% -145.34% -55.64% -432.00% -89.70% -1,226.24% -2,627.04% -2,198.72% -14,180.69%
Profit (Net Income) Margin		 -38.06% -15.12% -92.81% -169.59% -71.38% -490.05% -117.47% -1,367.84% -2,880.26% -2,432.25% -14,856.41%
Tax Burden Percent		 101.13% 40.50% 100.00% 100.00% 100.92% 100.14% 107.24% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 113.68% 349.03% 119.07% 116.69% 127.12% 113.28% 122.11% 111.55% 109.64% 110.62% 104.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -148.32% -54.65% 0.00% 0.00% 0.00% -2,656.30% -756.22% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -142.93% -48.98% 0.00% 0.00% 0.00% -2,639.78% -743.95% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 113.83% 38.27% 0.00% 0.00% 0.00% 2,514.03% 723.35% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -34.49% -16.38% 0.00% 0.00% 0.00% -142.27% -32.87% -239.82% -166.32% -122.80% -98.07%
Cash Return on Invested Capital (CROIC)		 -302.60% -402.47% -42.84% -87.17% -127.32% -1,074.23% -1,048.10% -2,312.02% -4,727.41% 0.00% 0.00%
Operating Return on Assets (OROA)		 -17.13% -6.09% 0.00% 0.00% 0.00% -65.14% -10.97% -46.03% -45.70% -18.90% -22.95%
Return on Assets (ROA)		 -19.69% -8.61% 0.00% 0.00% 0.00% -73.89% -14.37% -51.34% -50.10% -20.91% -24.04%
Return on Common Equity (ROCE)		 -34.49% -16.38% 0.00% 0.00% 0.00% -142.27% -32.87% -239.82% -166.32% -122.80% -98.07%
Return on Equity Simple (ROE_SIMPLE)		 -90.93% 0.00% 0.00% 0.00% 0.00% 0.00% -573.40% -410.91% -234.19% 0.00% -114.77%
Net Operating Profit after Tax (NOPAT)		 -17 -5.34 -27 -35 -22 -43 -26 -47 -53 -48 -73
NOPAT Margin		 -26.08% -7.49% -61.10% -113.60% -44.66% -316.56% -67.79% -900.46% -1,919.65% -1,617.59% -10,113.60%
Net Nonoperating Expense Percent (NNEP)		 -5.39% -5.66% -18.45% -15.09% -7.88% -16.52% -12.27% -17.32% -13.14% -9.11% -10.58%
Return On Investment Capital (ROIC_SIMPLE)		 -6.86% -2.02% - - - -14.74% - - - -11.76% -
Cost of Revenue to Revenue		 13.41% 9.68% 12.30% 11.23% 6.57% 16.61% 3.10% 14.95% 28.16% 16.38% 37.10%
SG&A Expenses to Revenue		 97.20% 80.73% 131.42% 188.52% 110.54% 359.86% 124.89% 885.51% 1,543.26% 1,250.35% 4,892.83%
R&D to Revenue		 26.64% 20.29% 43.57% 62.54% 46.68% 175.77% 68.84% 485.92% 1,270.95% 1,144.11% 9,618.07%
Operating Expenses to Revenue		 123.84% 101.02% 174.99% 251.06% 157.23% 535.63% 193.74% 1,371.43% 2,814.20% 2,385.38% 14,548.00%
Earnings before Interest and Taxes (EBIT)		 -22 -7.63 -35 -45 -28 -58 -34 -64 -73 -65 -103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -8.27 -35 -47 -29 -60 -35 -65 -75 -67 -103
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 13.01 10.35 6.94 5.78 4.16 3.44 0.00 7.27 4.81 4.30 3.64
Price to Tangible Book Value (P/TBV)		 14.71 11.01 7.40 5.97 4.28 3.71 0.00 7.94 5.06 4.46 3.74
Price to Revenue (P/Rev)		 8.72 8.30 0.00 0.00 0.00 5.11 0.00 50.21 103.90 244.64 1,359.12
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 34.21 41.72 31.94 33.75 31.54 13.23 0.00 48.27 104.04 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 8.29 7.68 0.00 0.00 0.00 3.92 0.00 44.22 83.09 186.84 970.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.75 0.68 1.31 1.09 0.90 2.28 4.30 2.48 1.42 0.94 0.73
Long-Term Debt to Equity		 0.75 0.68 0.67 1.09 0.90 2.28 4.30 2.48 1.42 0.94 0.73
Financial Leverage		 -0.80 -0.78 -0.76 -0.86 -0.92 -0.95 -0.97 -1.02 -1.03 -1.04 -1.03
Leverage Ratio		 2.24 2.80 3.59 2.87 2.35 2.65 2.53 2.25 1.89 1.69 1.41
Compound Leverage Factor		 2.54 9.79 4.28 3.35 2.99 3.00 3.08 2.51 2.07 1.87 1.48
Debt to Total Capital		 43.00% 40.49% 56.64% 52.23% 47.41% 69.47% 81.12% 71.28% 58.72% 48.55% 42.08%
Short-Term Debt to Total Capital		 0.00% 0.00% 27.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 43.00% 40.49% 29.09% 52.23% 47.41% 69.47% 81.12% 71.28% 58.72% 48.55% 42.08%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 57.00% 59.51% 43.36% 47.77% 52.59% 30.53% 18.88% 28.72% 41.28% 51.45% 57.92%
Debt to EBITDA		 -0.88 -0.81 0.00 0.00 0.00 -0.86 -0.83 -0.64 -0.64 -0.67 -0.66
Net Debt to EBITDA		 0.75 0.91 0.00 0.00 0.00 0.30 0.11 0.23 0.43 0.72 0.94
Long-Term Debt to EBITDA		 -0.88 -0.81 0.00 0.00 0.00 -0.86 -0.83 -0.64 -0.64 -0.67 -0.66
Debt to NOPAT		 -1.27 -1.19 0.00 0.00 0.00 -1.20 -1.15 -0.90 -0.90 -0.94 -0.92
Net Debt to NOPAT		 1.07 1.35 0.00 0.00 0.00 0.42 0.16 0.32 0.61 1.01 1.32
Long-Term Debt to NOPAT		 -1.27 -1.19 0.00 0.00 0.00 -1.20 -1.15 -0.90 -0.90 -0.94 -0.92
Altman Z-Score		 2.08 1.98 -0.81 -0.17 0.10 -2.70 0.00 -1.94 -0.84 0.61 1.12
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.55 4.15 2.46 8.46 9.89 7.08 6.72 8.43 9.93 11.57 13.39
Quick Ratio		 3.11 3.72 2.27 7.90 9.32 6.38 5.89 7.80 9.32 11.06 12.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -45 -24 -38 -52 -40 -64 -56 -72 -77 -63 -68
Operating Cash Flow to CapEx		 -4,996.71% 0.00% -24,257.34% 0.00% 0.00% -937,400.00% -68,725.00% -24,088.77% -97,980.49% -57,776.42% -1,128,250.00%
Free Cash Flow to Firm to Interest Expense		 -15.25 -4.29 -5.71 -6.89 -5.38 -8.24 -7.40 -9.84 -10.92 -9.11 -13.98
Operating Cash Flow to Interest Expense		 -10.19 -0.13 -5.21 -6.03 -4.23 -7.25 -5.82 -9.05 -11.41 -10.28 -13.82
Operating Cash Flow Less CapEx to Interest Expense		 -10.39 -0.13 -5.24 -6.03 -4.23 -7.25 -5.83 -9.08 -11.42 -10.29 -13.82
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.52 0.57 0.00 0.00 0.00 0.15 0.12 0.04 0.02 0.01 0.00
Accounts Receivable Turnover		 3.47 3.98 0.00 0.00 0.00 3.48 4.49 0.00 0.00 0.00 0.00
Inventory Turnover		 1.65 1.38 0.00 0.00 0.00 0.48 0.35 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 148.56 152.36 0.00 0.00 0.00 34.86 26.70 5.91 3.06 1.78 0.36
Accounts Payable Turnover		 1.32 1.46 0.00 0.00 0.00 0.48 0.30 0.18 0.12 0.09 0.04
Days Sales Outstanding (DSO)		 105.11 91.81 0.00 0.00 0.00 104.91 81.30 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 220.62 263.90 0.00 0.00 0.00 755.62 1,030.73 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 277.04 250.09 0.00 0.00 0.00 761.87 1,235.81 2,019.34 2,962.63 3,916.25 9,184.02
Cash Conversion Cycle (CCC)		 48.68 105.62 0.00 0.00 0.00 98.65 -123.77 -2,019.34 -2,962.63 -3,916.25 -9,184.02
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 52 36 30 27 23 18 19 11 5.17 -3.47 -11
Invested Capital Turnover		 5.69 7.30 0.00 0.00 0.00 8.39 11.16 -5.55 -0.98 -0.33 -0.09
Increase / (Decrease) in Invested Capital		 28 18 11 17 18 21 30 26 23 15 -4.85
Enterprise Value (EV)		 1,764 1,509 961 917 734 234 0.00 516 537 689 704
Market Capitalization		 1,856 1,630 1,087 1,077 935 305 0.00 585 672 902 985
Book Value per Share		 $1.20 $1.35 $1.34 $1.61 $2.03 $0.94 $0.76 $1.31 $2.29 $3.44 $5.25
Tangible Book Value per Share		 $1.06 $1.27 $1.26 $1.56 $1.97 $0.87 $0.65 $1.20 $2.17 $3.32 $5.11
Total Capital		 250 265 361 390 428 290 248 280 338 407 468
Total Debt		 108 107 205 204 203 202 201 200 199 198 197
Total Long-Term Debt		 108 107 105 204 203 202 201 200 199 198 197
Net Debt		 -91 -121 -127 -159 -202 -71 -27 -70 -135 -213 -281
Capital Expenditures (CapEx)		 0.61 0.00 0.14 0.00 0.00 0.01 0.06 0.28 0.08 0.12 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 34 26 20 20 16 11 12 2.61 -2.68 -11 -19
Debt-free Net Working Capital (DFNWC)		 233 255 351 383 421 284 240 272 331 400 460
Net Working Capital (NWC)		 233 255 251 383 421 284 240 272 331 400 460
Net Nonoperating Expense (NNE)		 7.89 5.45 14 17 13 23 19 24 27 24 34
Net Nonoperating Obligations (NNO)		 -91 -121 -127 -159 -202 -71 -27 -70 -135 -213 -281
Total Depreciation and Amortization (D&A)		 2.27 -0.64 -0.26 -2.04 -1.37 -1.09 -1.15 -1.44 -1.80 -2.00 -0.52
Debt-free, Cash-free Net Working Capital to Revenue		 15.90% 13.35% 0.00% 0.00% 0.00% 18.42% 23.70% 22.42% -41.43% -304.50% -2,562.76%
Debt-free Net Working Capital to Revenue		 109.27% 129.65% 0.00% 0.00% 0.00% 476.06% 488.69% 2,335.15% 5,112.90% 10,840.99% 63,395.45%
Net Working Capital to Revenue		 109.27% 129.65% 0.00% 0.00% 0.00% 476.06% 488.69% 2,335.15% 5,112.90% 10,840.99% 63,395.45%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.09) ($0.33) ($0.42) ($0.32) ($0.58) ($0.73) ($1.16) ($1.31) ($1.19) ($1.89)
Adjusted Weighted Average Basic Shares Outstanding		 126.04M 120.96M 124.30M 123.48M 111.05M 69.31M 61.73M 61.43M 61.17M 55.03M 57.09M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.09) ($0.33) ($0.42) ($0.32) ($0.58) ($0.73) ($1.16) ($1.31) ($1.19) ($1.89)
Adjusted Weighted Average Diluted Shares Outstanding		 126.04M 120.96M 124.30M 123.48M 111.05M 69.31M 61.73M 61.43M 61.17M 55.03M 57.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 119.20M 118.64M 117.04M 116.89M 115.76M 0.00 94.38M 61.65M 61.42M 61.08M 60.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -5.34 -27 -35 -22 -43 -26 -47 -53 -48 -73
Normalized NOPAT Margin		 -26.08% -7.49% -61.10% -113.60% -44.66% -316.56% -67.79% -900.46% -1,919.65% -1,617.59% -10,113.60%
Pre Tax Income Margin		 -37.63% -37.33% -92.81% -169.59% -70.73% -489.38% -109.53% -1,367.84% -2,880.26% -2,432.25% -14,856.41%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.31 -1.37 -5.24 -5.99 -3.69 -7.53 -4.52 -8.66 -10.37 -9.41 -20.99
NOPAT to Interest Expense		 -5.76 -0.96 -4.11 -4.68 -2.96 -5.52 -3.42 -6.36 -7.58 -6.93 -14.97
EBIT Less CapEx to Interest Expense		 -7.51 -1.37 -5.26 -5.99 -3.69 -7.53 -4.53 -8.70 -10.39 -9.43 -20.99
NOPAT Less CapEx to Interest Expense		 -5.96 -0.96 -4.13 -4.68 -2.96 -5.52 -3.43 -6.40 -7.59 -6.94 -14.97
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Arcutis Biotherapeutics' Financials

When does Arcutis Biotherapeutics's fiscal year end?

According to the most recent income statement we have on file, Arcutis Biotherapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Arcutis Biotherapeutics' net income changed over the last 6 years?

Arcutis Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$140.04 million in 2024, rising from -$19.26 million in 2018. The previous period was -$262.14 million in 2023. View Arcutis Biotherapeutics' forecast to see where analysts expect Arcutis Biotherapeutics to go next.

What is Arcutis Biotherapeutics's operating income?
Arcutis Biotherapeutics's total operating income in 2024 was -$128.40 million, based on the following breakdown:
  • Total Gross Profit: $177.41 million
  • Total Operating Expenses: $305.81 million
How has Arcutis Biotherapeutics revenue changed over the last 6 years?

Over the last 6 years, Arcutis Biotherapeutics' total revenue changed from $0.00 in 2018 to $196.54 million in 2024, a change of 19,654,200,000.0%.

How much debt does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics' total liabilities were at $191.35 million at the end of 2024, a 24.3% decrease from 2023, and a 3,347.7% increase since 2019.

How much cash does Arcutis Biotherapeutics have?

In the past 5 years, Arcutis Biotherapeutics' cash and equivalents has ranged from $53.64 million in 2022 to $96.45 million in 2021, and is currently $71.34 million as of their latest financial filing in 2024.

How has Arcutis Biotherapeutics' book value per share changed over the last 6 years?

Over the last 6 years, Arcutis Biotherapeutics' book value per share changed from 0.00 in 2018 to 1.35 in 2024, a change of 134.6%.


Related Companies

This page (NASDAQ:ARQT) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored